US 11,685,785 B2
Methods and antibodies for modulation of immunoresponse
Yen-Ta Lu, Taipei (TW); Chia-Ming Chang, Taipei (TW); Tsai-Yin Wei, Changhua County (TW); I-Fang Tsai, Taipei (TW); and Ling-Chiao Wu, Hsinchu (TW)
Assigned to Ascendo Biotechnology, Inc., Grand Cayman (KY)
Appl. No. 15/735,912
Filed by Ascendo Biotechnology, Inc., Grand Cayman (KY)
PCT Filed Jun. 12, 2016, PCT No. PCT/CN2016/085451
§ 371(c)(1), (2) Date Dec. 12, 2017,
PCT Pub. No. WO2016/197974, PCT Pub. Date Dec. 15, 2016.
Claims priority of provisional application 62/174,681, filed on Jun. 12, 2015.
Claims priority of provisional application 62/174,673, filed on Jun. 12, 2015.
Prior Publication US 2018/0362651 A1, Dec. 20, 2018
Int. Cl. A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 14/705 (2006.01); A61K 47/64 (2017.01); A61K 47/59 (2017.01); A61P 37/06 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/2845 (2013.01) [A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/59 (2017.08); A61K 47/643 (2017.08); A61P 37/06 (2018.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); A61K 38/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2319/70 (2013.01)] 13 Claims
 
1. A method of treating a disease associated with immune suppression, comprising administering a composition to a subject in need thereof, inhibiting PD-L1 expression, and reversing immune suppression or immune exhaustion in the subject, thereby treating a disease associated with immune suppression, wherein the composition comprises an antibody or antigen-binding portion thereof comprising:
(i) a heavy chain variable region comprising H-CDR1 having the sequence of SEQ ID NO:1, H-CDR2 having the sequence of SEQ ID NO:3, and H-CDR3 having the sequence of SEQ ID NO:5; or a heavy chain variable region comprising H-CDR1 having the sequence of SEQ ID NO:2, H-CDR2 having the sequence of SEQ ID NO:4, and H-CDR3 having the sequence of SEQ ID NO:6; and
(ii) a light chain variable region comprising L-CDR1 having the sequence of SEQ ID NO:7, L-CDR2 having the sequence of SEQ ID NO:9, and L-CDR3 having the sequence of SEQ ID NO:11; or a light chain variable region comprising L-CDR1 having the sequence of SEQ ID NO:8, L-CDR2 having the sequence of SEQ ID NO:10, and L-CDR3 having the sequence of SEQ ID NO:12.